15

May2019

Status Summary Of Innovative Medicine pCPA Negotiations As Of April 30, 2019

Each month the pCPA issues an update on the previous month’s negotiation activity. In Table 1 below you will find an overview of the new pCPA activity along with PDCI insights into recent developments for your interest. PDCI Target Insights (since last pCPA ... Read More

02

May2019

Julia Shen Joins PDCI Market Access!

PDCI is very pleased to welcome Julia Shen to the PDCI Team as Associate, Corporate Marketing and Policy Research, effective April 23, 2019! Ms. Shen’s addition to the team reflects PDCI’s focus on continued growth with our current and new clients and our objective to expand services responding to the ... Read More

01

Apr2019

Helena Koa Joins PDCI Market Access!

We are very pleased to announce that Helena Koa has joined PDCI as Manager, Market Access, effective today, April 1, 2019! Helena brings a wealth of knowledge and multi-disciplinary insights to PDCI: new product development, pricing and reimbursement, clinical research, health economics, and budget impact analyses. Helena’s experience spans over ... Read More

22

Mar2019

PDCI’s New Associate Director, HTA & Health Economics

PDCI is very excited to announce the promotion of Jennifer Haig to the position of Associate Director, HTA and Health Economics. This promotion is effective immediately. Jen has been with PDCI for 18 months, and in that time has ... Read More

20

Mar2019

Kimberly Robinson Joins PDCI Market Access!

PDCI is excited to announce and welcome Kimberly Robinson as the newest member of the PDCI team. Kimberly will be joining as the Director of Pricing and Market Access effective April 1, 2019 and will be responsible for the leadership of PDCI’s Pricing/PMPRB team. She will be based in the ... Read More

19

Mar2019

Federal Budget 2019 Supporting the Creation of a Canadian Drug Agency

Bill Morneau released his fourth Federal Budget in the House of Commons at 4pm today. Year in Review: In 2018, the federal budget established an independent Advisory Council on the Implementation of National Pharmacare. Over the past year, the Advisory Council, lead by Dr. Eric Hoskins, released a discussion paper in ... Read More

14

Mar2019

Status Summary of Innovative Medicine pCPA Negotiations as of February 28, 2019

Each month the pCPA issues an update on the previous month’s negotiation activity. In Table 1 below you will find an overview of the new pCPA activity along with PDCI insights into recent developments for your interest.... Read More

05

Mar2019

Health Canada and CADTH launch new initiative to provide Early Parallel Scientific Advice

On February 28, 2019, Health Canada and CADTH, with INESSS participating as an observer, announced a new joint Early Parallel Scientific Advice collaboration. The initiative seeks to provide more timely access to medicines for Canadians. Through this initiative, drug sponsors will obtain advice in parallel from Health Canada and ... Read More

22

Feb2019

CADTH Pharmaceutical Reviews Update – Issue 5

CADTH is launching a new Patient and Community Advisory Committee After talks with patient groups this past fall, CADTH is creating a 12-person advisory committee to discuss the experiences of patients and family caregivers in Canada. They invite nominations for those with extensive experience as a patient or family caregiver in ... Read More

15

Feb2019

Status Summary of Innovative Medicine pCPA Negotiations as of January 31, 2019

The Office of the pan-Canadian Pharmaceutical Alliance (pCPA) assesses brand name drug products for public funding either collectively or individually at the provincial and territorial levels. Each month the pCPA issues an update on the previous month’s negotiation activity. A file is complete once a Letter of Intent (LOI) is ... Read More